Compare Cytokinetics Inc (CYTK) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Uranium Energy Corp — how do they compare? Cytokinetics Inc trades at $62.48 (market cap $8.62B), while Uranium Energy Corp trades at $9.23 (market cap $4.53B). The key difference: Cytokinetics Inc is the larger of the two by market cap, and Cytokinetics Inc is trading nearer its 52-week high, Uranium Energy Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Uranium Energy Corp for 37 Days on average.
| CYTK | UEC | |
|---|---|---|
Market Cap | $8.62B | $4.53B |
Volume | 2,594,626 | 10,888,578 |
Sector | Health | Energy |
52-Week High | $87.26 | $20.14 |
52-Week Low | $54.76 | $9.04 |
Typical Hold Time | 19 Days | 37 Days |
Enterprise Value | $8.72B | $4.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
UEC trades at $9.24, down 2.43% on the day, amid a bearish technical signal with moving averages indicating selling pressure. The company reported a net loss of -$87.66M in 2025, with revenue of $66.84M and a deeply negative net income margin of -368.62%. Recent news highlights operational expansion to two mines, but earnings misses in Q1 and Q2 2026 raise concerns about sustainability despite a Q4 beat.
Wall Street analysts remain bullish with an 87.5% buy rating and a $16.06 consensus price target, citing U.S. uranium demand growth. However, high cash burn, reliance on financing, and unproven production sustainability pose significant risks. The stock offers speculative upside if operational execution improves, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
